Erasca Reports Positive Phase 1 Clinical Data for Pan-RAS Molecular Glue ERAS-0015

11/20/2026
Impact: 72
Healthcare

Erasca reported updated Phase 1 data for investigational pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. At a 32 mg once-daily dose, the therapy achieved a 44% confirmed objective response rate among patients with second-line-or-later KRAS G12X pancreatic ductal adenocarcinoma, including many heavily pretreated patients and those with G12R mutations. The company also reported favorable safety data and plans to initiate a potentially registration-enabling study; the article did not provide financial results or stock-price movements.

AI summary, not financial advice

Share: